Tag Archives: Genzyme

Sanofi's Aubagio to Square Off Against MS Injectables

By Ben Comer | Published: September 13, 2012
The most obvious competitors for Sanofi’s Aubagio, the second oral multiple sclerosis (MS) drug to receive FDA approval, would appear to be Novartis’ Gilenya, and Biogen Idec’s hotly anticipated BG-12, which has a PDUFA date scheduled for December 28. Both Gilenya and BG-12 are administered orally as opposed to injected, but execs at Genzyme – [...]
Posted in FDA, Regulatory, Safety, Strategy, pricing | Also tagged , , , | 2 Comments

Dare to Compare: Genzyme Bets on MS

By Ben Comer | Published: April 25, 2012
Riding positive data on a late-phase multiple sclerosis drug, Genzyme execs talked up the company’s willingness to go head-to-head against Rebif, EMD Serono and Pfizer’s blockbuster beta interferon. Genzyme execs didn’t go so far as to reiterate former CEO Henri Termeer’s 2010 prediction of $3 billion plus in potential sales for Lemtrada (alemtuzumab), but [...]
Posted in Biotech, Events, FDA, Global, IP, R&D, Regulatory, Safety, Sales, Strategy, Technology | Also tagged , , | 1 Comment

Fabry Disease Drug Shortage: Crisis Averted But No Long-Term Fix

By Guest Blogger | Published: March 23, 2012
By Amy Ritter. A critical drug that has experienced shortages is Genzyme’s Fabrazyme (agalsidase beta), the only enzyme replacement therapy approved in the US for Fabry disease. The drug was originally produced at the company’s Allston, Massachusetts plant. The Allston plant was plagued with quality problems, which resulted in a consent decree, temporary closure of the [...]
Posted in Guest Blog | Also tagged , , , | 1 Comment

Is Sanofi Right to Bank on MS Drug?

By Julian Upton | Published: February 23, 2011
Newswires have long been waiting for Sanofi-Aventis to officially announce its acquisition of US biotech company Genzyme, but what few analysts were expecting is just how much the transaction would hedge on one potentially controversial product. As the focus of Sanofi’s contingent value rights (CVR) approach, Genzyme’s multiple sclerosis treatment Lemtrada (also sold as Campath [...]
Posted in Safety, Strategy, pricing | Also tagged , , , , | 1 Comment

What Is Behind the Genzyme Job Cuts?

By Julian Upton | Published: September 15, 2010
Troubled biotech Genzyme’s (Cambridge, MA) planned elimination of over 1,000 jobs (10% of its 12,800 workforce, according to the Boston Globe) over the next 15 months is not related to the takeover bid from French giant Sanofi Aventis, the company has said.
Posted in Deals, Global, Strategy | Also tagged , , , , , | Leave a comment